Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery
Status:
Completed
Trial end date:
2016-02-06
Target enrollment:
Participant gender:
Summary
Many patients receiving opioid based analgesia after gynecologic laparoscopic surgery
experience postoperative nausea and vomiting (PONV) despite prophylaxis and treatment with
HT3 receptor antagonists. Although a high dose of ramosetron can cause adverse effects such
as headache or dizziness, the minimal effective dose of ramosetron in a high-risk patients is
unknown. The aim of this study is to determine the effective dose of ramosetron for
prophylaxis of PONV in a high-risk patients receiving intravenous opioid-based
patient-controlled analgesia after gynecological laparoscopic surgery.